+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Dyskinesia Market by Treatment Type, Dyskinesia Type, Route of Administration, Patient Care Settings - Global Forecast to 2030- Product Image
Dyskinesia Market by Treatment Type, Dyskinesia Type, Route of Administration, Patient Care Settings - Global Forecast to 2030- Product Image
Sale

Dyskinesia Market by Treatment Type, Dyskinesia Type, Route of Administration, Patient Care Settings - Global Forecast to 2030

  • PDF Icon

    Report

  • 187 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6082614
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Dyskinesia Market grew from USD 3.42 billion in 2024 to USD 3.66 billion in 2025. It is expected to continue growing at a CAGR of 7.30%, reaching USD 5.23 billion by 2030.

Setting the Stage for Dyskinesia Breakthroughs

The realm of dyskinesia poses complex clinical challenges that demand innovative solutions and strategic clarity. This executive summary illuminates the multifaceted nature of involuntary movement disorders, exploring the interplay between emerging therapies, patient care paradigms and regulatory shifts. By examining the current landscape through a lens of rigorous analysis, stakeholders can grasp the critical drivers shaping treatment adoption and access.

Against a backdrop of evolving neuroscience research and technological breakthroughs, this overview establishes the context for subsequent insights. It outlines how advancements in non-pharmacological modalities, novel drug classes and surgical interventions are converging to redefine standards of care. With an emphasis on evidence-based evaluation, this introduction sets the stage for a deep dive into transformative market shifts, policy impacts and actionable recommendations designed to inform strategic decision-making.

Navigating Major Shifts Reshaping Dyskinesia Treatment

Recent years have witnessed transformative shifts that are recalibrating the trajectory of dyskinesia management. The advent of precision medicine initiatives has enabled tailored pharmacological regimens, while digital health platforms capture real-world patient data to optimize therapy adjustments. Telemedicine adoption has expanded access to specialist consultations, bridging geographical barriers and streamlining follow-up care.

Simultaneously, wearable sensors and mobile applications are delivering continuous movement monitoring, empowering clinicians to detect early symptom fluctuations and refine treatment algorithms. Gene therapy research and neuromodulation advances are extending the horizon beyond symptomatic relief, aiming to address underlying pathophysiological mechanisms. Together, these shifts underscore a movement from reactive interventions toward proactive, data-driven care models that promise enhanced patient outcomes and sustainable healthcare delivery.

Assessing the Ripple Effects of 2025 US Tariffs on Dyskinesia Care

The implementation of United States tariffs in 2025 has introduced notable pressures across the dyskinesia supply chain, affecting raw materials for drug formulations, medical device components and surgical equipment imports. Manufacturers face elevated component costs, prompting strategic reevaluations of sourcing and production footprints. In response, some producers are accelerating near-shoring initiatives to mitigate tariff burdens and ensure continuity of supply.

These trade measures have also influenced pricing negotiations with payers and healthcare providers, leading organizations to explore value-based contracting models that link reimbursement to treatment outcomes. Consequently, stakeholders are prioritizing efficiency gains within manufacturing processes and logistics networks. Despite these headwinds, proactive adjustments in procurement strategies and collaborative partnerships are fostering resilience, enabling sustained investment in research and development while preserving market competitiveness.

Decoding Market Segmentation to Guide Strategic Focus

A granular examination of market segmentation reveals nuanced opportunities across therapeutic categories and patient journeys. When analyzing treatment type, the landscape spans non-pharmacological approaches that encompass behavioral therapy as well as physical therapy and rehabilitation, pharmacological treatments including anticholinergics, dopamine modulators, GABA agonists, NMDA receptor antagonists and VMAT2 inhibitors, and surgical treatments such as ablative surgery and deep brain stimulation. Further stratification by dyskinesia type uncovers distinct subgroups ranging from athetosis and chorea to dystonia-related dyskinesia, myoclonic dyskinesia, Parkinson’s dyskinesia, spasmodic torticollis and tardive dyskinesia. Route of administration plays a pivotal role in therapeutic adherence and patient preference, spanning intravenous and infusion-based systems, oral formulations, subcutaneous injections and transdermal patches. Patient care settings extend across home care environments, hospitals, research institutes and specialty clinics and rehabilitation centers, each presenting unique considerations for access, resource allocation and service delivery models.

Revealing Regional Dynamics Driving Growth and Access

Regional dynamics are instrumental in shaping market growth trajectories and access to dyskinesia interventions. In the Americas, advanced healthcare infrastructure and a strong emphasis on research and innovation underpin rapid adoption of cutting-edge therapies and neuromodulation devices. Regulatory frameworks that support expedited approvals are further catalyzing product launches.

Within Europe, Middle East and Africa, diverse regulatory landscapes and reimbursement policies create a mosaic of market entry pathways, driving manufacturers to tailor strategies to national requirements. Emerging economies in the region are prioritizing investments in specialist clinics and rehabilitation centers to address rising awareness and unmet clinical needs. The Asia-Pacific corridor demonstrates robust momentum as increasing healthcare expenditures, expanding patient populations and government initiatives bolster access to both pharmacological and non-pharmacological treatments. Collaborative partnerships between local and multinational players are fostering knowledge exchange and accelerating market penetration across these geographies.

Profiling Key Players Steering Dyskinesia Innovation

The competitive landscape is defined by a dynamic interplay between established pharmaceutical giants, pioneering device manufacturers and nimble biotechnology entrants. Industry leaders in the pharmaceutical sector are advancing their pipelines through strategic collaborations, in-licensing agreements and clinical trial expansions. Specialists in VMAT2 inhibitor development are securing regulatory milestones, while makers of neuromodulation platforms continue to enhance device precision and programming capabilities. Emerging biotechnology firms are exploring gene editing and RNA-based approaches to address dyskinetic pathophysiology at its source, often partnering with academic centers to accelerate translational research.

Concurrently, medtech companies are integrating digital interfaces into their systems to deliver remote monitoring and tele-therapy functionalities. This convergence of drug development, surgical innovation and digital health is fostering a highly competitive ecosystem, where cross-sector alliances and continuous product evolution serve as key differentiators.

Actionable Strategies for Industry Leadership in Dyskinesia Care

Industry leaders should prioritize a multidisciplinary approach to capture growth opportunities in dyskinesia care. Investing in targeted research and development across emerging drug classes and neuromodulation technologies will unlock novel treatment pathways. Strengthening supply chain resilience through diversified sourcing and smart manufacturing practices will mitigate trade-related disruptions and cost volatility.

Engaging with payers and patient advocacy groups to develop value-based reimbursement frameworks can accelerate market access and improve patient affordability. Embracing digital health solutions for remote monitoring and teleconsultation will enhance patient engagement and adherence, while also generating real-world evidence to support clinical and economic outcomes. Finally, forging collaborations with academic institutions and research consortia will facilitate knowledge sharing, streamline clinical trial execution and expedite regulatory submissions, ensuring sustained innovation and market leadership.

Ensuring Rigor Through a Robust Research Methodology

This report synthesizes comprehensive inputs from secondary research sources, peer-reviewed literature and regulatory documents to establish foundational intelligence. Primary research was conducted through structured interviews with key opinion leaders, clinicians, payers and patient advocates, providing nuanced perspectives on treatment adoption and unmet needs. Quantitative data were triangulated against multiple databases to validate consistency and accuracy.

Analytical frameworks were applied to dissect market segmentation, regional dynamics and competitive positioning, ensuring that findings reflect current industry realities. All methodologies underwent rigorous quality checks, including data validation protocols and expert panel reviews, to uphold the highest standards of research integrity. This robust hybrid approach ensures that conclusions and recommendations are grounded in empirical evidence and informed by stakeholder consensus.

Synthesis of Insights to Inform Future Directions

Bringing together insights from evolving treatment modalities, supply chain considerations and competitive dynamics offers a cohesive narrative for the future of dyskinesia management. The convergence of non-pharmacological therapies, novel drug classes and advanced neuromodulation underscores a transition toward personalized, data-driven care. Trade policy developments highlight the importance of flexible manufacturing and distribution strategies to navigate cost pressures.

Segmented analysis reveals distinct pathways for market entry and growth across therapeutic, route of administration and care delivery dimensions. Regional evaluations emphasize the need for tailored go-to-market approaches, while company profiling illuminates best practices in innovation and collaboration. By integrating these findings, industry stakeholders can chart a strategic course that aligns R&D priorities with market realities, optimizes resource allocation and ultimately delivers enhanced outcomes for patients living with dyskinesia.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Treatment Type
    • Non-Pharmacological Approaches
      • Behavioral Therapy
      • Physical Therapy & Rehabilitation
    • Pharmacological Treatments
      • Anticholinergics
      • Dopamine Modulators
      • GABA Agonists
      • NMDA Receptor Antagonists
      • VMAT2 Inhibitors
    • Surgical Treatments
      • Ablative Surgery
      • Deep Brain Stimulation (DBS)
  • Dyskinesia Type
    • Athetosis
    • Chorea
    • Dystonia-Related Dyskinesia
    • Myoclonic Dyskinesia
    • Parkinson’s Dyskinesia
    • Spasmodic Torticollis
    • Tardive Dyskinesia
  • Route of Administration
    • Intravenous (IV) & Infusion-Based
    • Oral
    • Subcutaneous
    • Transdermal
  • Patient Care Settings
    • Home Care
    • Hospitals
    • Research Institutes
    • Specialty Clinics & Rehabilitation Centers
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Abbott Laboratories
  • AbbVie Inc.
  • Addex Therapeutics Ltd.
  • Bukwang Pharmaceutical Co., Ltd
  • Clearmind Medicine Inc.
  • Ipsen Pharma SAS
  • IRLAB Therapeutics AB
  • Luye Pharma Group Ltd.
  • Medtronic PLC
  • Melior Pharmaceuticals
  • Mitsubishi Tanabe Pharma Corporation
  • Motac France Sarl
  • Neurocrine Biosciences, Inc.
  • Neurolixis Inc.
  • PharmaTher Holdings Ltd.
  • Prilenia Therapeutics B.V.
  • ReCode Therapeutics, Inc.
  • Serina Therapeutics, Inc.
  • SOM INNOVATION BIOTECH, SA
  • Supernus Pharmaceuticals, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Toray Industries, Inc.
  • Vistagen Therapeutics, Inc.
  • Voyager Therapeutics, Inc.
  • Zydus Lifesciences Limited

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Dyskinesia Market, by Treatment Type
8.1. Introduction
8.2. Non-Pharmacological Approaches
8.2.1. Behavioral Therapy
8.2.2. Physical Therapy & Rehabilitation
8.3. Pharmacological Treatments
8.3.1. Anticholinergics
8.3.2. Dopamine Modulators
8.3.3. GABA Agonists
8.3.4. NMDA Receptor Antagonists
8.3.5. VMAT2 Inhibitors
8.4. Surgical Treatments
8.4.1. Ablative Surgery
8.4.2. Deep Brain Stimulation (DBS)
9. Dyskinesia Market, by Dyskinesia Type
9.1. Introduction
9.2. Athetosis
9.3. Chorea
9.4. Dystonia-Related Dyskinesia
9.5. Myoclonic Dyskinesia
9.6. Parkinson’s Dyskinesia
9.7. Spasmodic Torticollis
9.8. Tardive Dyskinesia
10. Dyskinesia Market, by Route of Administration
10.1. Introduction
10.2. Intravenous (IV) & Infusion-Based
10.3. Oral
10.4. Subcutaneous
10.5. Transdermal
11. Dyskinesia Market, by Patient Care Settings
11.1. Introduction
11.2. Home Care
11.3. Hospitals
11.4. Research Institutes
11.5. Specialty Clinics & Rehabilitation Centers
12. Americas Dyskinesia Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Dyskinesia Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Dyskinesia Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Abbott Laboratories
15.3.2. AbbVie Inc.
15.3.3. Addex Therapeutics Ltd.
15.3.4. Bukwang Pharmaceutical Co., Ltd
15.3.5. Clearmind Medicine Inc.
15.3.6. Ipsen Pharma SAS
15.3.7. IRLAB Therapeutics AB
15.3.8. Luye Pharma Group Ltd.
15.3.9. Medtronic PLC
15.3.10. Melior Pharmaceuticals
15.3.11. Mitsubishi Tanabe Pharma Corporation
15.3.12. Motac France Sarl
15.3.13. Neurocrine Biosciences, Inc.
15.3.14. Neurolixis Inc.
15.3.15. PharmaTher Holdings Ltd.
15.3.16. Prilenia Therapeutics B.V.
15.3.17. ReCode Therapeutics, Inc.
15.3.18. Serina Therapeutics, Inc.
15.3.19. SOM INNOVATION BIOTECH, SA
15.3.20. Supernus Pharmaceuticals, Inc.
15.3.21. Teva Pharmaceutical Industries Ltd.
15.3.22. Toray Industries, Inc.
15.3.23. Vistagen Therapeutics, Inc.
15.3.24. Voyager Therapeutics, Inc.
15.3.25. Zydus Lifesciences Limited
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. DYSKINESIA MARKET MULTI-CURRENCY
FIGURE 2. DYSKINESIA MARKET MULTI-LANGUAGE
FIGURE 3. DYSKINESIA MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL DYSKINESIA MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL DYSKINESIA MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL DYSKINESIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2024 VS 2030 (%)
FIGURE 14. GLOBAL DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS DYSKINESIA MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS DYSKINESIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES DYSKINESIA MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES DYSKINESIA MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA DYSKINESIA MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA DYSKINESIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC DYSKINESIA MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC DYSKINESIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. DYSKINESIA MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. DYSKINESIA MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. DYSKINESIA MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL DYSKINESIA MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL DYSKINESIA MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL DYSKINESIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL DYSKINESIA MARKET SIZE, BY BEHAVIORAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL DYSKINESIA MARKET SIZE, BY PHYSICAL THERAPY & REHABILITATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL DYSKINESIA MARKET SIZE, BY ANTICHOLINERGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL DYSKINESIA MARKET SIZE, BY DOPAMINE MODULATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL DYSKINESIA MARKET SIZE, BY GABA AGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL DYSKINESIA MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL DYSKINESIA MARKET SIZE, BY VMAT2 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL DYSKINESIA MARKET SIZE, BY ABLATIVE SURGERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL DYSKINESIA MARKET SIZE, BY DEEP BRAIN STIMULATION (DBS), BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL DYSKINESIA MARKET SIZE, BY ATHETOSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL DYSKINESIA MARKET SIZE, BY CHOREA, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL DYSKINESIA MARKET SIZE, BY DYSTONIA-RELATED DYSKINESIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL DYSKINESIA MARKET SIZE, BY MYOCLONIC DYSKINESIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL DYSKINESIA MARKET SIZE, BY PARKINSON’S DYSKINESIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL DYSKINESIA MARKET SIZE, BY SPASMODIC TORTICOLLIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL DYSKINESIA MARKET SIZE, BY TARDIVE DYSKINESIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL DYSKINESIA MARKET SIZE, BY INTRAVENOUS (IV) & INFUSION-BASED, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL DYSKINESIA MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL DYSKINESIA MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL DYSKINESIA MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL DYSKINESIA MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL DYSKINESIA MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL DYSKINESIA MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL DYSKINESIA MARKET SIZE, BY SPECIALTY CLINICS & REHABILITATION CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS DYSKINESIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES DYSKINESIA MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 56. CANADA DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 57. CANADA DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 58. CANADA DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 59. CANADA DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 60. CANADA DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 61. CANADA DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 62. CANADA DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 63. MEXICO DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 64. MEXICO DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 65. MEXICO DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 66. MEXICO DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 67. MEXICO DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 68. MEXICO DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 69. MEXICO DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 70. BRAZIL DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 71. BRAZIL DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 72. BRAZIL DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 73. BRAZIL DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 74. BRAZIL DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 75. BRAZIL DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 76. BRAZIL DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 77. ARGENTINA DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 78. ARGENTINA DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 79. ARGENTINA DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 80. ARGENTINA DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 81. ARGENTINA DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 82. ARGENTINA DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 83. ARGENTINA DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 84. EUROPE, MIDDLE EAST & AFRICA DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 85. EUROPE, MIDDLE EAST & AFRICA DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 86. EUROPE, MIDDLE EAST & AFRICA DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 87. EUROPE, MIDDLE EAST & AFRICA DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 88. EUROPE, MIDDLE EAST & AFRICA DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 89. EUROPE, MIDDLE EAST & AFRICA DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 90. EUROPE, MIDDLE EAST & AFRICA DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 91. EUROPE, MIDDLE EAST & AFRICA DYSKINESIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 92. UNITED KINGDOM DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 93. UNITED KINGDOM DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 94. UNITED KINGDOM DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 95. UNITED KINGDOM DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 96. UNITED KINGDOM DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 97. UNITED KINGDOM DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 98. UNITED KINGDOM DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 99. GERMANY DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 100. GERMANY DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 101. GERMANY DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 102. GERMANY DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 103. GERMANY DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 104. GERMANY DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 105. GERMANY DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 106. FRANCE DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 107. FRANCE DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 108. FRANCE DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 109. FRANCE DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 110. FRANCE DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 111. FRANCE DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 112. FRANCE DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 113. RUSSIA DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 114. RUSSIA DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 115. RUSSIA DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 116. RUSSIA DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 117. RUSSIA DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 118. RUSSIA DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 119. RUSSIA DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 120. ITALY DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 121. ITALY DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 122. ITALY DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 123. ITALY DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 124. ITALY DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 125. ITALY DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 126. ITALY DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 127. SPAIN DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 128. SPAIN DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 129. SPAIN DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 130. SPAIN DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 131. SPAIN DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 132. SPAIN DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 133. SPAIN DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 134. UNITED ARAB EMIRATES DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 135. UNITED ARAB EMIRATES DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 136. UNITED ARAB EMIRATES DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 137. UNITED ARAB EMIRATES DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 138. UNITED ARAB EMIRATES DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 139. UNITED ARAB EMIRATES DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 140. UNITED ARAB EMIRATES DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 141. SAUDI ARABIA DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 142. SAUDI ARABIA DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 143. SAUDI ARABIA DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 144. SAUDI ARABIA DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 145. SAUDI ARABIA DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 146. SAUDI ARABIA DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 147. SAUDI ARABIA DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 148. SOUTH AFRICA DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 149. SOUTH AFRICA DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 150. SOUTH AFRICA DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 151. SOUTH AFRICA DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 152. SOUTH AFRICA DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 153. SOUTH AFRICA DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 154. SOUTH AFRICA DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 155. DENMARK DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 156. DENMARK DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 157. DENMARK DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 158. DENMARK DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 159. DENMARK DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 160. DENMARK DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 161. DENMARK DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 162. NETHERLANDS DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 163. NETHERLANDS DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 164. NETHERLANDS DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 165. NETHERLANDS DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 166. NETHERLANDS DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 167. NETHERLANDS DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 168. NETHERLANDS DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 169. QATAR DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 170. QATAR DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 171. QATAR DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 172. QATAR DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 173. QATAR DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 174. QATAR DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 175. QATAR DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 176. FINLAND DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 177. FINLAND DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 178. FINLAND DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 179. FINLAND DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 180. FINLAND DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 181. FINLAND DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 182. FINLAND DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 183. SWEDEN DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 184. SWEDEN DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 185. SWEDEN DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 186. SWEDEN DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 187. SWEDEN DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 188. SWEDEN DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 189. SWEDEN DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 190. NIGERIA DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 191. NIGERIA DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 192. NIGERIA DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 193. NIGERIA DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 194. NIGERIA DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 195. NIGERIA DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 196. NIGERIA DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 197. EGYPT DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 198. EGYPT DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 199. EGYPT DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 200. EGYPT DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 201. EGYPT DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 202. EGYPT DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 203. EGYPT DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 204. TURKEY DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 205. TURKEY DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 206. TURKEY DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 207. TURKEY DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 208. TURKEY DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 209. TURKEY DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 210. TURKEY DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 211. ISRAEL DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 212. ISRAEL DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 213. ISRAEL DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 214. ISRAEL DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 215. ISRAEL DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 216. ISRAEL DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 217. ISRAEL DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 218. NORWAY DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 219. NORWAY DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 220. NORWAY DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 221. NORWAY DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 222. NORWAY DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 223. NORWAY DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 224. NORWAY DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 225. POLAND DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 226. POLAND DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 227. POLAND DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 228. POLAND DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 229. POLAND DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 230. POLAND DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 231. POLAND DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 232. SWITZERLAND DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 233. SWITZERLAND DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 234. SWITZERLAND DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 235. SWITZERLAND DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 236. SWITZERLAND DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 237. SWITZERLAND DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 238. SWITZERLAND DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 239. ASIA-PACIFIC DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 240. ASIA-PACIFIC DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 241. ASIA-PACIFIC DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 242. ASIA-PACIFIC DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 243. ASIA-PACIFIC DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 244. ASIA-PACIFIC DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 245. ASIA-PACIFIC DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 246. ASIA-PACIFIC DYSKINESIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 247. CHINA DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 248. CHINA DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 249. CHINA DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 250. CHINA DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 251. CHINA DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 252. CHINA DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 253. CHINA DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 254. INDIA DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 255. INDIA DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 256. INDIA DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 257. INDIA DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 258. INDIA DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 259. INDIA DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 260. INDIA DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 261. JAPAN DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 262. JAPAN DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 263. JAPAN DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 264. JAPAN DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 265. JAPAN DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 266. JAPAN DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 267. JAPAN DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 268. AUSTRALIA DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 269. AUSTRALIA DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 270. AUSTRALIA DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 271. AUSTRALIA DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 272. AUSTRALIA DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 273. AUSTRALIA DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 274. AUSTRALIA DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 275. SOUTH KOREA DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 276. SOUTH KOREA DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 277. SOUTH KOREA DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 278. SOUTH KOREA DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 279. SOUTH KOREA DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 280. SOUTH KOREA DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 281. SOUTH KOREA DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 282. INDONESIA DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 283. INDONESIA DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 284. INDONESIA DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 285. INDONESIA DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 286. INDONESIA DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 287. INDONESIA DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 288. INDONESIA DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 289. THAILAND DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 290. THAILAND DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 291. THAILAND DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 292. THAILAND DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 293. THAILAND DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 294. THAILAND DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 295. THAILAND DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 296. PHILIPPINES DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 297. PHILIPPINES DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 298. PHILIPPINES DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 299. PHILIPPINES DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 300. PHILIPPINES DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 301. PHILIPPINES DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 302. PHILIPPINES DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 303. MALAYSIA DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 304. MALAYSIA DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 305. MALAYSIA DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 306. MALAYSIA DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 307. MALAYSIA DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 308. MALAYSIA DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 309. MALAYSIA DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 310. SINGAPORE DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 311. SINGAPORE DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 312. SINGAPORE DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 313. SINGAPORE DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 314. SINGAPORE DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 315. SINGAPORE DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 316. SINGAPORE DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 317. VIETNAM DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 318. VIETNAM DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 319. VIETNAM DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 320. VIETNAM DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 321. VIETNAM DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 322. VIETNAM DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 323. VIETNAM DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 324. TAIWAN DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 325. TAIWAN DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
TABLE 326. TAIWAN DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 327. TAIWAN DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 328. TAIWAN DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
TABLE 329. TAIWAN DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 330. TAIWAN DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 331. DYSKINESIA MARKET SHARE, BY KEY PLAYER, 2024
TABLE 332. DYSKINESIA MARKET, FPNV POSITIONING MATRIX, 2024

Companies Mentioned

The companies profiled in this Dyskinesia market report include:
  • Abbott Laboratories
  • AbbVie Inc.
  • Addex Therapeutics Ltd.
  • Bukwang Pharmaceutical Co., Ltd
  • Clearmind Medicine Inc.
  • Ipsen Pharma SAS
  • IRLAB Therapeutics AB
  • Luye Pharma Group Ltd.
  • Medtronic PLC
  • Melior Pharmaceuticals
  • Mitsubishi Tanabe Pharma Corporation
  • Motac France Sarl
  • Neurocrine Biosciences, Inc.
  • Neurolixis Inc.
  • PharmaTher Holdings Ltd.
  • Prilenia Therapeutics B.V.
  • ReCode Therapeutics, Inc.
  • Serina Therapeutics, Inc.
  • SOM INNOVATION BIOTECH, SA
  • Supernus Pharmaceuticals, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Toray Industries, Inc.
  • Vistagen Therapeutics, Inc.
  • Voyager Therapeutics, Inc.
  • Zydus Lifesciences Limited

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages187
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 3.66 Billion
Forecasted Market Value ( USD ) by 2030 $ 5.23 Billion
Compound Annual Growth Rate7.3%
Regions CoveredGlobal
No. of Companies Mentioned26

Related Topics

Related Reports

Primary Ciliary Dyskinesia Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Primary Ciliary Dyskinesia Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 121 Pages
  • Global
From
Dyskinesia- Pipeline Insight, 2025 - Product Image

Dyskinesia- Pipeline Insight, 2025

  • Clinical Trials
  • 80 Pages
  • Global
From
Radiotherapy Market by Technology, Product, Application, End User, Treatment, Equipment, Dosage, Modality, Patient Care, Development Phase - Global Forecast to 2030 - Product Image

Radiotherapy Market by Technology, Product, Application, End User, Treatment, Equipment, Dosage, Modality, Patient Care, Development Phase - Global Forecast to 2030

  • Report
  • 183 Pages
  • Global
From
Integrated Patient Care Systems - Global Strategic Business Report - Product Image

Integrated Patient Care Systems - Global Strategic Business Report

  • Report
  • 348 Pages
  • Global
From
Interactive Patient Care (IPC) Market Innovations and Strategic Insights Report - Market Data, Trends, Market Potential, Competitive Analysis and Growth Forecasts (2024 to 2032) - Product Image

Interactive Patient Care (IPC) Market Innovations and Strategic Insights Report - Market Data, Trends, Market Potential, Competitive Analysis and Growth Forecasts (2024 to 2032)

  • Report
  • 154 Pages
  • Global
From

About the Dyskinesia Market

Dyskinesia is a neurological disorder characterized by involuntary, repetitive movements. It is most commonly associated with the use of certain central nervous system drugs, such as antipsychotics and levodopa. Dyskinesia can cause a range of physical symptoms, including jerky movements, tremors, and difficulty with coordination. It can also lead to psychological symptoms, such as anxiety and depression. The dyskinesia market is composed of a range of pharmaceutical companies that produce drugs to treat the disorder. These companies develop and market medications that can reduce the severity of symptoms and improve quality of life. Many of these drugs are approved by the FDA and are available in both generic and brand-name forms. Some of the companies in the dyskinesia market include AbbVie, Allergan, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Teva Pharmaceuticals. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.